The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
An article from
Dive Brief
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
Published May 15, 2026
Aardvark Therapeutics announced that the Food and Drug Administration had put a clinical hold on ARD-101 on May 14, 2026.
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved…
Pfizer and Arvinas give disappointing breast cancer drug to Rigel
